Background: Gout is a common inflammatory arthritis with rising global prevalence and health burden, especially in the Asia-pacific regions. Ethnicity may play a significant role suggesting lifestyle and/or genetic predisposition, but studies in Asia are limited 1,2 . Objectives: Our study sought to assess the demographic and clinical factors of gout in the multi-ethnic Singapore and describe the burden and treatment pattern in our patients. Methods: 282 adults with rheumatologist-diagnosed gout were recruited from rheumatology clinics of an academic medical centre in Singapore. Data on demographic and lifestyle features, medical conditions, gout severity and treatment were obtained. Results: 282 subjects were recruited and 92.6% were men. There were 77% Chinese, 18.8% Malays and 2.5% Indians, compared to Singapore's population makeup (74%, 13% and 9% respectively). Mean age at recruitment was 52.6 years (SD 16.1) while age at gout onset was 42.5 years (SD 16.7). 34.4% received primary or no education; 67.0% were employed and 20.7% retired. 22.7% were current alcohol drinkers while 50.7% were teetotalers. 23.4% were current smokers. Mean body mass index (BMI) was 28.1kg/m 2 (SD 6.0), 26.6% had BMI ≥30kg/m 2 while 69.9% had BMI ≥25kg/m 2 . Prevalence of hypertension was 56.7%, diabetes mellitus 18.8%, dyslipidemia 48.2% and chronic kidney disease (CKD, defined as glomerular filtration rate <60ml/min/1.73m
2 ) 32.4%. Malays had significantly less alcohol intake (1.9%) but higher proportions of diabetes (32.1%), CKD (50.9%) and obesity (54.7%), compared with Chinese subjects (26.3%, 16.1%, 28.6% and 19.8% respectively, all Ps <0.05) . Gout severity was rated moderate by 30.9% and severe in 50.4%; 69.3% suffered ≥3 attacks in 6 months. Mean SU was 477.8μmol/L (SD 130.8). 80.1% were on allopurinol. Subjects (22.3%) who achieved serum urate (SU) ≤360μmol/L, when compared to those with SU >360μmol/L, were more likely to be on urate lowering therapy (82.5% vs 60.7%, P=0.001), on higher mean allopurinol dose [337 mg/d (SD 166) vs 233 mg/d (SD 140), P<0.001] and statin (54.8% vs 33.3%, P=0.003). There were no significant differences amongst ethnicities for SU levels, gout severity and number of attacks. Conclusions: Gout has substantial health burden in Singapore. Hypertension, dyslipidemia and obesity are more prevalent in our gout subjects compared to our population. Despite notably less alcohol intake compared with other cohorts 3-5 , Singapore Malays seemed to suffer higher prevalence and comorbidities of gout.
Majority of patients had moderate to severe disease but less than 25% achieved target SU levels highlighting suboptimal management of gout locally. Background: Axial spondyloarthritis include non-radiographic spondyloarthritis (nr-SpA) and ankylosing spondylitis (AS); they reveal the extent of sacroiliitis assessed by conventional x-ray or MRI (1). The natural history of nr-SpA follows various evolution patterns; smoking, male gender, high levels of inflammatory markers or initial radiographic lesions are among predictor factors of progression to AS (2). Objectives: The objective of the present study was to compare features related to progression of nr-SpA patients versus AS patients undergoing biological therapy with an anti-TNF agent. Methods: This was an observational, cross-sectional study including 94 patients with nr-SpA and AS under continuous anti-TNF therapy for at least six months. SPSS 20.0 was used to analyze data with a P value of 0.05. Results: Out of the selected study group, 69 patients were diagnosed with AS having a mean age of 44.8±10.8, while 25 patients had nr-SpA. Patients with nr-SpA were aged 32.1±6.6 years old and 40% of them were women, a rate significantly than in the AS group (P=0.05). Mean age at disease onset was 30.7 years for the AS subgroup versus only 23.8 years for patients with nr-SpA (P<0.001). AS patients presented a significantly higher value of the BMI compared to nr-SpA (27 versus 24.7 kg/m 2, P<0.001). 91% of patients had positive HLA B27 and 7.4% had a positive family history of SpA, with no significant differences between the two subgroups. A higher level of CRP was noticed in AS patients (P=0.038).In the study cohort the time interval from symptom onset to establishing a diagnosis was of 39.9±55.6 months, with a mean delay interval of 2.32 years for patients with nr-SpA and higher, of 3.5 for patients with AS (P=0.01).
Conclusions:
The nr-SpA group had a considerably higher percentage of females compared to the AS subgroup. AS patients presented higher values of CRP at follow-up visits as opposed to nr-SpA patients. There were no significant differences between nr-SpA and AS patients regarding BASDAI or PtGA scores, smoking status or frequency of uveitis. The presence of HLA B27 did not differ between the two subgroups, thus it might not be a reliable predictive factor of progression. Background: Fracture is one of the most common and important comorbidities in rheumatoid arthritis (RA) patients, especially patients who use glucocorticoids (GC). However, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) which is the gold standard of diagnosing and monitoring osteoporosis is not a useful tool for predicting new fracture in RA patients. Previous studies suggested the possibility of trabecular bone score (TBS) as a useful predictor for incident fracture. Objectives: We aimed to evaluate the accuracy of TBS combined with clinical risk factors or BMD for prediction of new fracture in patients with RA. Methods: A total of 100 female RA patients were enrolled with assessment of TBS, BMD, and clinical risk factors for fracture. During follow-up period, we calculated the incident rate of all fractures. After dividing the patients according to the use of GCs, we compared baseline characteristics and fracture-free survival between two groups. We compared accuracies of TBS, BMD, clinical risk factors for fracture and their combinations for predicting new fractures using areas under the receiver operator characteristic (ROC) curve (AUC). Results: A total of 14 fractures in 12 patients were occurred among 100 patients during follow-up (428.8 person-years): 9 among the 44 in GC users and 5 in 56 GC non-users. Incidence of fracture was not different between two groups (log-rank test, p=0.27). AUC for incident fracture prediction of TBS alone [AUC 0.54, 95% confidence interval (CI) 0.35-0.72] was comparable with TBS combined with L-spine BMD (AUC 0.54, 95% CI 0.36-0.71) or with hip BMD (AUC 0.55, 95% CI 0.37-0.73). Accuracy for prediction of new fracture is increased when TBS was combined with age and history of previous fracture (AUC 0.74, 95% CI 0.62-0.85). In GC users, history of previous fracture alone (AUC 0.79, 95% CI 0.62-0.97) showed the best accuracy for predicting new fracture among TBS, BMD, clinical risk factors for fracture and their combinations. Conclusions: TBS combined with age and previous history of fracture showed the highest accuracy for predicting new fracture compared to TBS or BMD alone or their combinations in RA patients. In GC users, history of previous fracture alone showed the highest accuracy for predicting new fracture. Background: All-cause and cause-specific mortality is increased in patients with systemic lupus erythematosus (SLE) and Rheumatoid Arthritis (RA) when compared to the general population. Mortality can be attributed to the disease per se, side effects of drugs and effect of comorbidities. The survival of patients has improved over the past years when compared to historical controls Objectives: The objective is to describe all-case of mortality in patients with SLE and RA in a university hospital. Methods: This is an observational, descriptive, and cross-sectional study. We included all patients with SLE and RA hospitalized during 1998 to 2014. The cause of death was obtained from medical records and classified according to International Classification of Diseases (ICD)-10. We made a descriptive analysis of all-cause of mortality of both diseases. Results: We analyzed 1,330 medical records, of which 215 died in hospital. The respiratory insufficiency was the most common mortality diagnosis in both diseases (RA 29%, SLE 24.1%), followed by sepsis (RA 25%, SLE 20.4%). The all-cause of mortality of SLE and RA are shown in Table 1 . Of the 467 RA hospital admissions, the 5.1% died, and of the 863 SLE hospital admissions, the 22.1% died. 
